

Application site pain or discomfort was reported in 25% and 19% of patients who were treated with the **BrainsWay D**, and in less than 1% and 4.1% of the patients who received the sham (placebo) treatment. Pain in the jaw was reported in 10.2% of patients who received the **BrainsWay D** treatment, and in less than 1% of the patients who received the sham treatment. This indicates that these side effects are caused by the **BrainsWay D** treatment. You should inform the administrator of the treatment if you feel pain or discomfort during the therapy. The helmet of the **BrainsWay D** System may be slightly adjusted on your head to relieve the pain or discomfort. Pain and discomfort associated with treatment usually gets better or goes away altogether with successive treatments.

Headaches were reported in 47% of patients who received the treatment, and in 36% of the patients who received the sham (placebo) treatment. This indicates that headaches were not necessarily caused as a result of the **BrainsWay D** treatment. Headaches usually get better or go away altogether with successive treatments. Headaches may also be relieved by using common over-the-counter pain medications such as acetaminophen. Other side effects which may occur but are not necessarily caused by **BrainsWay D** treatment include muscle twitching, back pain, anxiety or insomnia.

BrainsWay D Treatment - Effectiveness Information

The safety and effectiveness of **BrainsWay D** treatment of Major Depressive Disorder was demonstrated in a prospective, double blind, randomized, controlled, multi-center trial. The study was conducted at 20 study sites in the United States (13 sites), Israel (4 sites), Germany (2 sites) and Canada (1 site). During the initial treatment phase, TMS sessions were performed daily for 4 weeks and during the maintenance phase, subjects were treated twice a week for another 12 weeks.

The primary endpoint was the change from baseline (i.e., the starting score before treatment) in a standard scale for measuring depression symptoms, known as the Hamilton Depression Rating Scale (HDRS). The model estimated mean change from baseline in HDRS scores in **BrainsWay D** treatment group across 5 weeks compared to the sham group was statistically significant. The response rate (meaning the percent of patients who had a reduction in HDRS scores of at least 50%) was significantly better in the **BrainsWay D** treatment group compared to the sham group. The remission rate (meaning the percent of patients who had a reduction in HDRS score to less than 10 points) was significantly better in the **BrainsWay D** treatment group compared to the sham group.

There was a statistically significant improvement in quality of life in patients treated with **BrainsWay D**, according to the difference in Q-LES-Q scores between **BrainsWay D** and the sham groups. These results do not include 13% of subjects who did not receive the adequate **BrainsWay D** treatment regimen and therefore, the effectiveness of the therapy was not as good in these subjects. Of these subjects receiving reduced intensity of **BrainsWay D** treatment, some had a high Motor Threshold and therefore could not receive the adequate **BrainsWay D** treatment regimen. Your Motor Threshold will be measured prior to the first treatment session and if it is too high, your doctor will discuss with you the appropriateness of receiving the **BrainsWay D** treatment.

Another few of these subjects did not receive the adequate **BrainsWay D** treatment regimen, due to discomfort or pain during the therapy.

The efficacy of the **BrainsWay D** treatment was still seen at 16 weeks, based on a statistically significant change from baseline in HDRS scores ($p=0.0259$) and a significantly better response rate in the **BrainsWay D** treatment group compared to the sham group ($p=0.0086$). The efficacy of the **BrainsWay D** treatment, based on statistically significant differences in the CGI-S, CGI-I, PGI and GAF scores, was demonstrated at 5 weeks and maintained at 16 weeks. No significant differences were found in the SF-36 scores; however, all the SF-36 Quality of Life parameters were better in the **BrainsWay D** treatment group than in the sham group.

You may ask your doctor for more information regarding the clinical study.

Summary Information

The **BrainsWay D** System has been shown to be safe and effective for the treatment of Major Depressive Disorder (MDD). You should consult the treatment with your doctor to ensure that it is the right treatment for you.

Most patients who benefit from **BrainsWay D** experience results by the third or fourth week of treatment. Some patients may experience results in less time. **BrainsWay D** treatment should be administered daily for four weeks, following by 12 weeks of biweekly treatment. This is the treatment schedule that has been demonstrated as safe and effective in the clinical study.

As with any antidepressant treatment, there is a risk that your depression symptoms may worsen during **BrainsWay D** treatment. Your depression symptoms may also worsen if you stop taking antidepressant medications before the beginning of the treatment. Inform your doctor immediately if your depression symptoms worsen.

The **BrainsWay D** treatment has not been evaluated to be safe and effective for patients with suicidal ideation or who have recently attempted suicide.



BrainsWay

BrainsWay. All Rights Reserved.

www.brainsway.com

Tel: 1-(855)-200-DTMS

contact@brainsway-usa.com



PATIENT MANUAL

BrainsWay Treatment for Major Depressive Disorder

This patient manual is a supplement to
BrainsWay system Instructions for use.

If you are considering **BrainsWay D** treatment for depression, please review this patient manual and discuss with your doctor in order to better understand:

- How **BrainsWay D** treatment works
- Who can be treated with **BrainsWay D**
- Who should not be treated with **BrainsWay D**
- Precautions and warnings
- Potential side-effects

Introduction to BrainsWay D Treatment

You have been diagnosed with Major Depressive Disorder and your doctor has recommended to be treated with **BrainsWay D** to treat symptoms of your depression. **BrainsWay D** treatment has been shown to be safe and effective in the treatment of patients with Major Depressive Disorder.

Your Health Care Provider (psychiatrist or physician) will review your medical and depression history to help determine if **BrainsWay D** treatment is appropriate for you or not.

The treatment is performed under your psychiatrist's supervision. Neither anesthesia nor sedation is required. You will be awake and alert during the treatment sessions. The treatment sessions include daily treatments for a period of 4 weeks. Each treatment session lasts approximately 20-30 minutes. Your doctor may consider further biweekly maintenance treatments in-order to continue treating your depression.

How Does BrainsWay D Treatment Work?

BrainsWay D is a non-invasive procedure, involving stimulation of a part of the brain called the Left Prefrontal Cortex. The stimulation activates the nerve cells in this region of the brain and improves depressive symptoms. The stimulation is produced by a treatment "coil" contained in a helmet. During the treatment, the helmet is gently positioned on the left front side of your head, over this region of the brain. Short pulses of electricity sent through the treatment coil generate magnetic fields that turn on and off very rapidly. These magnetic fields are similar to those used in magnetic resonance imaging (MRI) systems. The magnetic field goes through the head and induces a weak electrical current that briefly activates the nerve cells in this region of the brain and improves depressive symptoms.

When Should BrainsWay D Treatment be Used?

Indications for Use

BrainsWay D is indicated for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.

When Should BrainsWay D Treatment Not be Used?

BrainsWay D treatment delivers a magnetic field that could cause any metal objects that are near the device to move or to get hot. The treatment should not be used if you have metal implants in or around your head (except for standard amalgam dental fillings). **BrainsWay D** should not be used if you have implanted electronic devices in your body. These implants could cause serious injury or death if **BrainsWay D** is used. You should tell your doctor if you have any metal devices or objects in your head or body in order to determine if those devices could be affected by the treatment.

BrainsWay D Treatment Safety Information

Safety of **BrainsWay D** was demonstrated in a clinical study involving 233 patients with moderate to severe Major Depressive Disorder. The patients ranged in age from 22 to 68 years. This section summarizes the adverse events and side effects reported in the clinical study with **BrainsWay D**.

- There were no deaths in patients who took part in the clinical trial.
- Systemic side effects such as weight gain, dry mouth and sexual problems were not observed.
- Tests of memory function during treatment showed no change during the clinical trial.

You should discuss the warnings and precautions related to **BrainsWay D** treatment with your doctor to determine if any precautions should be taken prior to or during your treatment.

Seizures

There was one case of a seizure (also called convulsions) reported in the clinical study using **BrainsWay D** System. This seizure was due to high alcohol consumption during the night before the treatment. 3 more seizures (out of approximately 50,000 treatment sessions) were reported in other studies using **BrainsWay D** System in subjects on high doses of antidepressants, which are known to increase the risk of a seizure. None of the subjects who have experienced **BrainsWay D** induced seizure have suffered lasting physical sequelae.

You should discuss with your doctor if you have had a seizure, or if you have a medical condition or change in a medical condition which may put you at increased risk of having a seizure, e.g., brain injury, change in medications, change in electrolyte balance, etc. Your doctor will decide if it is appropriate for you to receive **BrainsWay D** treatment.

Worsening of Depression or Suicidality

Your antidepressant medications may be tapered down prior to the treatment of **BrainsWay D**. You may feel uncomfortable or be unable to tolerate the tapering of medications. Your depression may become worse before you begin to see an improvement in your symptoms. Increased mood lability and suicidality may also result from tapering medications. **BrainsWay D** may require several weeks of treatment before symptom improvement occurs.

Your doctor will monitor you for worsening depressive symptoms or signs or symptoms of suicidal behavior during the course of the treatment. You should also inform your doctor if you have any behavioral changes, such as worsening of depression, suicide attempts and ideations, increased aggressiveness, euphoria or irritability. Your family and caregiver should also be aware that if such behavioral changes appear, they should inform the treatment administrator immediately. Your doctor will determine whether **BrainsWay D** should be discontinued and, if so, what other treatment options are available.

Long-Term Safety

The long-term safety of the **BrainsWay D** has been demonstrated in a clinical study. During the full course of 16 weeks of ongoing treatment, the therapy was safely tolerated. Furthermore, no negative effects of treatment were seen during a 3 month follow-up period. Longer term effects of exposure to the treatment are not known. However, exposure to other devices (such as MRI scanners) with the same type and strength of magnetic fields produced by **BrainsWay D** coil are not associated with significant short-term or long-term safety concerns.

The safety and effectiveness of **BrainsWay D** System has not been established in the following patient populations or clinical conditions through a controlled clinical trial:

- Patients who have had no prior antidepressant medication failure.
- Patients who cannot tolerate withdrawal of antidepressant medications.
- Patients who are concurrently taking antidepressant medications.
- Patients who have a suicide plan or have recently attempted suicide.
- Patients who do not meet DSM IV criteria for major depressive disorder.
- Patients less than 22 years of age or older than 68 years of age.
- Patients with history of substance abuse, obsessive compulsive disorder or post-traumatic stress disorder.
- Patients with a psychotic disorder, including schizoaffective disorder, schizophrenic disorder, bipolar disease, or major depression with psychotic features.
- Patients with psychoses or with psychiatric emergencies where a rapid clinical response is needed, such as immediate suicide risk.
- Patients with neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma or with primary or secondary tumors in the CNS.
- Patients with metal in or around the head, including metal plates, aneurysm coils, cochlear implants, ocular implants, deep brain stimulation devices and stents.
- Patients with implants controlled by physiological signals, including stimulators.
- Patients with major depressive disorder who have failed to receive
- Patients who are pregnant or nursing.

During **BrainsWay D** treatment a loud clicking sound is emitted. Patients must use earplugs with a rating of at least 30 dB of noise reduction. There have been no reports of hearing loss after the treatment during the clinical study when earplugs were used.

Adverse Events

Table 1 below presents the adverse events reported in the clinical study in $\geq 5\%$ or more of the patients who received the **BrainsWay D** treatment or the sham (placebo) treatment. Safety information is provided from all patients who were treated in the clinical study.

Table 1 - Adverse Events

Anticipated Event	Deep TMS Treatment (N=111 Subjects)		Sham Treatment (N=112 Subjects)		p-value
	No of Subjects	Incidence	No of Subjects	Incidence	
Pain in Jaw	11	10.2%	1	0.8%	0.0017
Application Site Discomfort	21	19.4%	5	4.1%	0.0003
Application Site Pain	27	25.0%	1	0.8%	<.0001
Headache	51	47.2%	44	36.4%	0.1079
Muscle Twitching	7	6.5%	2	1.7%	0.0878
Back Pain	5	4.6%	10	8.3%	0.2977
Anxiety	6	5.6%	9	7.4%	0.6042
Insomnia	8	7.4%	9	7.4%	1.0000